• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Ssytemic effects of intravenous polyriboinosinic-polyribocytidylic acid in man.

作者信息

Cornell C J, Smith K A, Cornwell G G, Burke G P, McIntyre O R

出版信息

J Natl Cancer Inst. 1976 Dec;57(6):1211-6. doi: 10.1093/jnci/57.6.1211.

DOI:10.1093/jnci/57.6.1211
PMID:1069859
Abstract

To investigate the systemic, clinical and laboratory effects of iv polyriboinosinic-polyribocytidylic acid (poly I-poly C), 32 doses of poly I-poly C were administered to 22 patients. Doses between 1 and 10 mg/kg induced the formation of serum interferon (IF) and fever. Whereas a direct relationship was seen between the poly I-poly C dose and fever, serum IF levels were not significantly changed by increasing the dose of poly I-poly C over a log range from 1 to 10 mg/kg. Transient abnormalities were noted in liver function tests in 4 of 13 patients who received greater than 6.0 mg/kg. Other laboratory changes were confined to an increase in the absolute granulocyte count that paralleled fever development and abnormalities in coagulation parameters of 1 patient. In vitro lymphocyte DNA synthesis in response to mitogens was transiently impaired at times corresponding to serum IF appearance. These studies have established dose levels of poly I-poly C that can be safely administered to man with minimal toxicity and result in IF induction.

摘要

相似文献

1
Ssytemic effects of intravenous polyriboinosinic-polyribocytidylic acid in man.
J Natl Cancer Inst. 1976 Dec;57(6):1211-6. doi: 10.1093/jnci/57.6.1211.
2
A phase I-II trial of multiple-dose polyriboinosic-polyribocytidylic acid in patieonts with leukemia or solid tumors.
J Natl Cancer Inst. 1976 Sep;57(3):599-602. doi: 10.1093/jnci/57.3.599.
3
Initial clinical trials in cancer patients of polyriboinosinic-polyribocytidylic acid stabilized with poly-L-lysine, in carboxymethylcellulose [poly(ICLC)], a highly effective interferon inducer.聚肌苷酸-聚胞苷酸与聚-L-赖氨酸稳定结合,并存在于羧甲基纤维素中(聚(ICLC)),这是一种高效的干扰素诱导剂,在癌症患者中进行的初步临床试验。
Cancer Res. 1979 May;39(5):1645-50.
4
The fever induced by polyriboinosinic:polyribocytidylic acid is not related to interferon synthesis in the rabbit's hypothalamus.
J Interferon Res. 1991 Jun;11(3):165-9. doi: 10.1089/jir.1991.11.165.
5
Modified polyriboinosinic-polyribocytidylic acid complex: induction of serum interferon, fever, and hypotension in rabbits.修饰的聚肌苷酸-聚胞苷酸复合物:对兔血清干扰素、发热及低血压的诱导作用
Antimicrob Agents Chemother. 1980 Jan;17(1):49-54. doi: 10.1128/AAC.17.1.49.
6
Clinical studies of an interferon inducer, polyriboinosinic-polyribocytidylic acid [poly (I)-poly (C)], in children.干扰素诱导剂聚肌苷酸-聚胞苷酸[聚(I)-聚(C)]在儿童中的临床研究。
J Infect Dis. 1977 Jul;136(1):50-8. doi: 10.1093/infdis/136.1.50.
7
Phase II trial of a complex polyriboinosinic-polyribocytidylic acid with poly-L-lysine and carboxymethyl cellulose in the treatment of children with acute leukemia and neuroblastoma: a report from the Children's Cancer Study Group.复合聚肌苷酸-聚胞苷酸与聚-L-赖氨酸及羧甲基纤维素治疗儿童急性白血病和神经母细胞瘤的II期试验:儿童癌症研究组报告
Cancer Res. 1985 Nov;45(11 Pt 2):5904-9.
8
An Eastern Cooperative Oncology Group phase I-II pilot study of polyriboinosinic-polyribocytidylic acid poly-L-lysine complex in patients with metastatic malignant melanoma.东部肿瘤协作组关于聚肌苷酸-聚胞苷酸聚-L-赖氨酸复合物用于转移性恶性黑色素瘤患者的I-II期初步研究。
J Biol Response Mod. 1985 Dec;4(6):664-8.
9
Phase I-II trials of poly IC stabilized with poly-L-lysine.聚-L-赖氨酸稳定的聚肌胞苷酸的I-II期试验。
Cancer Treat Rep. 1978 Nov;62(11):1907-12.
10
Modified polyriboinosinic-polyribocytidylic acid complex: sustained interferonemia and its physiological associates in humans.修饰的聚肌苷酸-聚胞苷酸复合物:人类持续性干扰素血症及其生理相关因素
Infect Immun. 1979 Sep;25(3):831-7. doi: 10.1128/iai.25.3.831-837.1979.

引用本文的文献

1
An Overview of Vaccine Adjuvants: Current Evidence and Future Perspectives.疫苗佐剂概述:当前证据与未来展望
Vaccines (Basel). 2022 May 22;10(5):819. doi: 10.3390/vaccines10050819.
2
Exploration of Pattern Recognition Receptor Agonists as Candidate Adjuvants.探索模式识别受体激动剂作为候选佐剂。
Front Cell Infect Microbiol. 2021 Oct 6;11:745016. doi: 10.3389/fcimb.2021.745016. eCollection 2021.
3
Antigen delivery by filamentous bacteriophage fd displaying an anti-DEC-205 single-chain variable fragment confers adjuvanticity by triggering a TLR9-mediated immune response.
展示抗DEC-205单链可变片段的丝状噬菌体fd递送抗原,通过触发TLR9介导的免疫反应赋予佐剂活性。
EMBO Mol Med. 2015 Apr 17;7(7):973-88. doi: 10.15252/emmm.201404525. Print 2015 Jul.
4
Targeting of the non-mutated tumor antigen HER2/neu to mature dendritic cells induces an integrated immune response that protects against breast cancer in mice.针对非突变肿瘤抗原 HER2/neu 靶向成熟树突状细胞可诱导整合免疫反应,从而保护小鼠免受乳腺癌的侵害。
Breast Cancer Res. 2012 Mar 7;14(2):R39. doi: 10.1186/bcr3135.
5
The microbial mimic poly IC induces durable and protective CD4+ T cell immunity together with a dendritic cell targeted vaccine.微生物模拟物聚肌苷酸胞苷酸(poly IC)与一种靶向树突状细胞的疫苗共同诱导持久且具有保护性的CD4+ T细胞免疫。
Proc Natl Acad Sci U S A. 2008 Feb 19;105(7):2574-9. doi: 10.1073/pnas.0711976105. Epub 2008 Feb 6.
6
Evaluation of the in vitro pyrogen test system based on proinflammatory cytokine release from human monocytes: comparison with a human whole blood culture test system and with the rabbit pyrogen test.基于人单核细胞促炎细胞因子释放的体外热原试验系统的评价:与人类全血培养试验系统及家兔热原试验的比较
Clin Diagn Lab Immunol. 2002 May;9(3):588-97. doi: 10.1128/cdli.9.3.588-597.2002.
7
Interferons and interferon inducers: development of clinical usefulness and therapeutic promise.干扰素与干扰素诱导剂:临床应用的发展及治疗前景
Drugs. 1982 Jan-Feb;23(1-2):37-55. doi: 10.2165/00003495-198223010-00002.
8
The interferon renaissance: molecular aspects of induction and action.干扰素的复兴:诱导与作用的分子层面
Microbiol Rev. 1981 Jun;45(2):244-66. doi: 10.1128/mr.45.2.244-266.1981.